These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12040531)

  • 1. Improving outcomes in transplantation.
    Brugger W
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):23-6. PubMed ID: 12040531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.
    Belhadj K; Delfau-Larue MH; Elgnaoui T; Beaujean F; Beaumont JL; Pautas C; Gaillard I; Kirova Y; Allain A; Gaulard P; Farcet JP; Reyes F; Haioun C
    Ann Oncol; 2004 Mar; 15(3):504-10. PubMed ID: 14998857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.
    Magni M; Di Nicola M; Devizzi L; Matteucci P; Lombardi F; Gandola L; Ravagnani F; Giardini R; Dastoli G; Tarella C; Pileri A; Bonadonna G; Gianni AM
    Blood; 2000 Aug; 96(3):864-9. PubMed ID: 10910898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.
    Lazzarino M; Arcaini L; Bernasconi P; Alessandrino EP; Gargantini L; Cairoli R; Orlandi E; Astori C; Brusamolino E; Pagnucco G; Colombo AA; Calatroni S; Iacona I; Regazzi MB; Morra E
    Br J Haematol; 2002 Jan; 116(1):229-35. PubMed ID: 11841421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearing minimal residual disease with rituximab consolidation therapy.
    Brugger W
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):33-7. PubMed ID: 15042533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
    Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L
    Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N; Ishibashi K; Uno H; Hino N
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.
    Jacobsen E; Freedman A
    Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab: enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma.
    Gisselbrecht C; Mounier N
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):28-33. PubMed ID: 12652462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation.
    Mangel J; Buckstein R; Imrie K; Spaner D; Franssen E; Pavlin P; Boudreau A; Pennell N; Combs D; Berinstein NL
    Ann Oncol; 2003 May; 14(5):758-65. PubMed ID: 12702531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
    Gianni AM; Magni M; Martelli M; Di Nicola M; Carlo-Stella C; Pilotti S; Rambaldi A; Cortelazzo S; Patti C; Parvis G; Benedetti F; Capria S; Corradini P; Tarella C; Barbui T
    Blood; 2003 Jul; 102(2):749-55. PubMed ID: 12663455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
    Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
    Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem-cell transplantation in non-Hodgkin's lymphoma: improving outcome.
    Gianni AM; Berinstein NL; Evans PA; López-Guillermo A; Solano C
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S35-42. PubMed ID: 12710589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
    Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
    J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic advances for indolent lymphomas].
    Ogura M
    Nihon Rinsho; 2000 Mar; 58(3):682-94. PubMed ID: 10741147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplantation strategies for patients with follicular lymphoma.
    Buske C; Dreyling M; Unterhalt M; Hiddemann W
    Curr Opin Hematol; 2005 Jul; 12(4):266-72. PubMed ID: 15928482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in autologous stem cell transplantation for follicular lymphoma.
    Schmitz N
    Anticancer Drugs; 2001 Jun; 12 Suppl 2():S21-4. PubMed ID: 11508933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin’s lymphoma in the rituximab era.
    Escobar IG; Sánchez de Ibarguen BC; de Juan VC; Alonso CM; García MM; Ruíz AC; Pulla MP
    Tumori; 2015; 101(1):2-7. PubMed ID: 25702654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.